AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Curious Clinicians
90 - Less Sugar, More Blood
May 29, 2024
Exploring how SGLT2 inhibitors impact hemoglobin and hematocrit levels in heart failure patients, revealing surprising effects on red blood cell mass and EPO levels. Delving into the complex interplay of SGLT2 inhibitors, iron, and hemoglobin, and the significance of point of care cytosolic iron testing.
23:10
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- SGLT2 inhibitors cause erythrocytosis by boosting epoproduction in the liver.
- These inhibitors decrease hepcidin and ferritin levels, influencing iron metabolism and cellular health.
Deep dives
SGLT2 Inhibitors and Hemoglobin Increase
SGLT2 inhibitors have been found to lead to an increase in hemoglobin levels. This effect is linked to an enhancement in epoproduction, potentially originating from the liver. The exact mechanism of this elevation in hemoglobin may involve various signaling pathways, as these drugs alter master switches to prioritize cellular health.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode